2539 results about "Pharmacy medicine" patented technology

The invention discloses a method for in vitro slow release performance evaluation of a slow and controlled release preparation based on the overflow principle. A container with an upper outlet and a lower outlet is adopted to serve as a release tank, a to-be-detected medicine and a dissolution medium are placed in the release tank, a stirring device is adopted in the release tank to perform stirring, and the dissolution medium is added from the lower outlet of the release tank through a peristaltic pump; the dissolution medium dissolved with the medicine is taken away through the overflow from the upper outlet so as to offset medicine absorption or metabolism, and the slow and controlled release speed of the medicine, the total medicine overflow quantity and the total release amount are calculated by measuring the concentration of the medicine contained in the dissolution medium flowing out, the volume of the release tank and the overflow quantity. According to the method, the releasing degree of the slow and controlled release medicine can be evaluated accurately, the effective medicine release time of the slow and controlled release preparation is evaluated, and slow release performances of the slow and controlled release preparation are evaluated comprehensively.

The present disclosure relates to a medicament delivery device comprising a housing having a proximal end and contains a container of medicament positioned within the housing in a medicament container holder. The medicament container can be dual chambered, for example a pre-filled medicament container having a needle, a dose of medicament and one or more sliding stoppers. The medicament container holder can be configured with a recess or pocket to accommodate the loading of a dual chambered container and interact with an inside surface of the housing to rotationally fix the container holder relative to the housing and the medicament container. A tubular activation member, e.g., a needle cover, is slidably positioned within a housing of the delivery device to move from a first position to a second position, and then to a final locked position. A plunger rod can only move proximally relative to the needle cover when the needle cover is in the second position.

A device may include a data acquisition layer comprising a patient information collector and a drug information collector, each operable to ingest patient-specific clinical data and drug-specific data, respectively. A device may include an analysis engine comprising a multi-criteria ranking engine configured to compute composite suitability score for candidate medications by weighting one or more of medication efficacy, medication safety, medication resistance, medication cost, or patient-specific coverage factors. A device may include a presentation layer comprising a summary dashboard configured to display a ranked medication recommendation set produced by the analysis engine.

The present application refers to a process and a system for collecting, storing, analyzing and visualizing electrocardiographic (ECG) data collected by portable ECG device (100) with embedded wireless communication technology, additionally containing a portable ECG device (100), a hermetically sealed box (200) of medicines containing a lock system comprising a lock (220), a first device (310) to be accessed by the patient, a second device (320) to be accessed by the medical professional, a platform for graphical display of ECG data, and a remote data storage and processing central. The hardware board of the portable ECG device contains wireless communication technology, global positioning system (GPS), start button (141), rechargeable battery charging port, and an equipment configuration and programming port. The battery (120) is Li-Ion type, containing LEDs indicating device operation, and waiting for connection. The battery status is displayed on the app display. In one embodiment, an electrode (130B) is positioned on the bottom cover (110B) of the housing (110A, 110B, 110C) of the ECG device (100).

This invention discloses a blood purification device and medical system. The blood purification device includes: a device housing; a blood purifier; a blood tubing assembly, the blood tubing assembly including a first blood tubing connecting a human blood vessel to the inlet of the blood purifier and a second blood tubing connecting the outlet of the blood purifier to the human blood vessel; a power assembly including a blood pump for driving blood flow within the blood tubing assembly, a first replenishment pump for allowing anticoagulant solution to flow into the first blood tubing, and / or a second replenishment pump for allowing calcium solution to flow into the second blood tubing; and a blood component analysis component disposed within the device housing, the blood component analysis component being used to detect collected blood samples. This design facilitates the appropriate adjustment of anticoagulant drugs and calcium ions in the blood purification circuit.

A vial adapter for connecting to an injection vial comprises an adapter body comprising a top wall and a sidewall, the sidewall projecting from the top wall in a longitudinal direction to form a receptacle with a distal side of the top wall. The receptacle is configured to receive at least a portion of a barrel head of an injection vial. A movable part comprises a base part and a tipped cannula fixed to the base part. The tipped cannula extends through the top wall into the receptacle, wherein the movable part is movable relative to the adapter body in a longitudinal direction. The tipped cannula comprises an elongated fluid channel, a tipped distal end configured to penetrate a pierceable stopper of the injection vial, and a channel aperture located inside the receptacle and located proximally offset from the tipped distal end.

This application provides a method for preparing compound I-b or a pharmaceutically acceptable salt thereof, wherein (S)-N-methylamino-1-(2-thiophene)-1-propanol reacts with 4-fluorobenzo[1,3]dioxolane in a system containing sodium hydride and potassium benzoate to obtain compound I-b. This method has short steps, mild reaction conditions, and is simple to operate, making it suitable for industrial scale-up; moreover, the obtained product has high purity and low isomer content.

This invention belongs to the field of biopharmaceuticals and provides a keratin YK93-8, its encoding nucleic acid molecule, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or whose genome integrates the nucleic acid molecule, as well as a preparation method and a pharmaceutical composition thereof. It also provides the application of the above-mentioned keratin YK93-8 and other products in the preparation of drugs for treating benign prostatic hyperplasia, lymphoma, melanoma, breast cancer, lung cancer, analgesia, lactation, uterine fibroids, coagulation, etc.

The present invention relates to a near-infrared responsive drug delivery system, wherein a near-infrared responsive drug delivery system comprising a near-infrared responsive drug delivery formulation is provided, and the near-infrared responsive drug delivery formulation may include a near-infrared responsive material that generates heat in response to near-infrared rays, and a drug loading formulation that releases a loaded drug as its structure is deformed by the heat generated from the near-infrared responsive material.

This invention discloses an N-alkoxyacetamide compound, its pharmaceutical composition, and its applications. Specifically, this invention provides a compound as shown in formula (II), its pharmaceutically acceptable salt, or its stereoisomer, which can effectively treat or prevent chronic kidney disease, congestive heart failure, hypertension, hypertension complications, or primary aldosteronism; for example, hypertension or primary aldosteronism.

The application discloses a kind of Zhang Xizheng pure Chinese medicine theory prescription medicine digital inheritance and intelligent analysis system.The system includes disease and syndrome differentiation rule engine subsystem, prescription three-way search subsystem, drug knowledge enhancement subsystem, medical record intelligent search subsystem, Zhang Xizheng school review subsystem and large language model interaction subsystem.The method performs the following steps: LLM clinical information extraction and disease prediction (extract symptoms, tongue, pulse, and 8 big disease classification prediction), disease and syndrome differentiation KB rule matching (8 big disease classification x multiple syndrome type weighted scoring matching), multi-source search (prescription three-way search+drug knowledge double-way vector recall and prescription-drug dynamic association+medical record multidimensional mixed scoring search), LLM fusion generation (inject all search results Zhang Xizheng school special prompt word generation theory prescription medicine analysis report) and Zhang Xizheng school four-dimensional review (western medicine perspective+air theory+drug use principles+theory prescription medicine consistency).The present application first realizes the computer formalization expression of Zhang Xizheng "disease differentiation before syndrome differentiation" mode and "air monism" theory, based on "Medical Western Medicine Record" 172 prescriptions+213 drugs / medical theory / medical conversation+137 cases to build a complete knowledge search and intelligent analysis system, with the ability of western medicine perspective+air theory+drug use principles+theory prescription medicine consistency.

The application discloses a kind of intelligent optical genetic and microdosing spatiotemporal coordination measurement and control system based on catheter assembly, belong to biomedical engineering and automatic control cross technical field.The system obtains optical power spatial distribution model by intelligent optical genetic module, obtains drug concentration distribution model and carries out fluid back pressure monitoring and prevents blocking by microdosing module, then maximum coincidence space is calculated by spatiotemporal coordination optimization module and space relative coordinate deviation instruction is generated, finally, through catheter assembly execution module, instruction is responded to adaptively adjust the physical spacing of light guide and dosing channel.The advantage of the application is that the defects of light medicine dispersion field mislocation and microtubule easy blockage in the prior art can be effectively solved, and high-precision in-vivo light medicine collaborative intervention is realized.

This invention discloses a traditional Chinese medicine composition for treating male infertility due to liver stagnation and kidney deficiency, its preparation method, and its application, belonging to the fields of traditional Chinese medicine pharmaceutical technology and andrological reproductive health technology. The composition is formulated with Bupleurum chinense, Tribulus terrestris, Cynomorium songaricum, Cuscuta chinensis, Cornus officinalis, and Epimedium brevicornu in specific weight proportions, following the principles of soothing the liver and relieving stagnation, tonifying the kidney and replenishing essence, and unblocking the meridians to treat impotence. This invention employs an alcohol-water dual-phase fractional extraction process, and can be prepared into various dosage forms such as granules, capsules, and tablets. Pharmacological experiments have confirmed that the composition of this invention can increase sperm density and progressively motile sperm rate, improve penile tissue nitric oxide synthase (NOS) activity, regulate reproductive hormones, and reduce testicular oxidative damage; serum pharmacochemistry and metabolomics have clarified the active components entering the bloodstream and their pathways of action. This invention features a refined formulation, abundant medicinal resources, and simple preparation, making it suitable for large-scale production and clinical application in treating male infertility due to liver stagnation and kidney deficiency.

This invention belongs to the field of medical information technology and discloses an intelligent detection system and method for drug compatibility risks. The method includes: establishing and maintaining a multi-dimensional drug compatibility knowledge base based on a graph database; automatically acquiring drug information to be executed and retrieving the target patient's hospital-wide medication history through a standardized medical information interaction interface; calculating the estimated blood drug concentration of each historical drug at the current moment based on a pharmacokinetic compartment model to construct an effective drug list; performing combination analysis on the drugs to be executed and the effective drug list, and executing a multi-level compatibility risk detection algorithm, wherein the detection algorithm includes multi-drug combination cascade reaction risk prediction based on a graph neural network model; and generating and outputting graded early warning information containing risk levels and specific descriptions based on the detection results. This invention achieves dynamic, accurate, and real-time detection of complex multi-drug combination risks, significantly improving medication safety.

[Problem] The purpose of the present invention is to provide a portable anticancer agent container for preventing exposure and infection to the human body caused by chemical solution leakage that arises during a removal operation of a coupling connector at the time of system cleaning using a cleaning solution. [Solution] Provided is a pressurization-type drug injector having a drug exposure preventive function and having a system cleaning function, the pressurization-type drug injector comprising: a reservoir that has a chemical solution filling opening and a chemical solution discharging opening; a pressurization deformation means that undergoes pressurization and deformation by the injection of a chemical solution and that pushes out the chemical solution by a force caused by restoration of the pressurization and deformation; a flow rate control means that adjusts the flow rate of the chemical solution by resistance; a system cleaning port that includes a cleaning solution injection opening, a chemical solution filling opening, and a liquid discharging opening; and a case that contains therein said reservoir, said pressurization deformation means, and said system cleaning port. The case has openings respectively in the vicinity of the chemical solution filling opening, the system cleaning injection opening, and the chemical solution discharging opening. The chemical solution being filled is filled into the pressurization deformation means from the chemical solution filling opening of the reservoir, and moves from the chemical solution discharging opening of the reservoir to the exterior of the container via the flow rate control means. A cleaning solution is injected from the injection opening of the cleaning port arranged downstream from the flow rate control means, and moves to the exterior of the container. The pressurization-type drug injector having a drug exposure preventive function is characterized in that the periphery of the cleaning port is completely covered by a sterile seal, and thus, the cleaning port injection opening is kept clean until use.

The disclosure provides a method for treating a subject afflicted with a tumor, e.g., derived from a non-small cell lung cancer (NSCLC), comprising administering to the subject a combination of a (a) chemotherapy, (b) an anti-PD-1 antibody or an anti-PD-L1 antibody, and (c) an anti-CTLA-4 antibody, wherein the chemotherapy is administered for a period of time that is less than the standard.

Disclosed in the present invention are a crystalline form of a compound, a preparation method therefor, an active pharmaceutical ingredient or composition comprising same, and a use thereof in the preparation of an extracellular histone inhibitor. The crystalline form of the compound of the present application has high crystallinity, good solid properties and high stability, crystallization conditions are mild, the operation is simple, the process is stable, the cost is low, and the crystalline form of the compound is adapted to be stored as an active pharmaceutical ingredient and produce a formulation product.

A composition contains a BCS Class II or IV drug that is acid-base solubilized with a pharmaceutically acceptable acid, and which is complexed with β-cyclodextrin. The β-cyclodextrin complexed drug exhibits enhanced bioavailability. The drug may be formulated for oral administration and / or to exhibit rapid release when administered. Preferable compositions may contain no crosslinked or polymerized non-active components.

The present invention provides a pharmaceutical composition for treating cancer, the pharmaceutical composition comprising a nucleic acid that suppresses the expression of Chromosome 11 Open Reading Frame 97 (C11orf97). With the present invention, it becomes possible to treat cancer.

The utility model relates to medical instrument technical field, concretely is tracheal stent that can be absorbed and contains drug coating, including the casing of cylindrical cylinder shape, the casing includes longitudinal skeleton, ring skeleton, the drug groove of outward expansion and assembly groove, the drug coating strip is filled in the drug groove of outward expansion, the outside of casing is pasted with the film, the film includes the shrinkage film, contact touch and closed film, the utility model discloses through the degradation of closed film in patient trachea first, releases the stress on the corresponding casing at the drug groove of outward expansion, makes the drug groove of outward expansion, and the outer diameter of whole tracheal stent expands along with it, and drives drug coating strip synchronous expansion and presses outward and expands the patient place, realizes that the stent can be in the patient's body self -degradation, and the expansion force of stent can be slowly released in the process of degradation, thereby offset the stent wall thinning after degradation or the trachea natural growth leads to the stent expansion force reduction, dynamically maintained the expansion force of stent, increased the stability of stent.

The pharmaceutical composition according to the present invention is used at specific therapeutic regimen and dosage, and can be usefully used for the prevention or treatment of fibrosis.

The present application relates to the field of medicinal chemistry and pharmacotherapy, and in particular to a class of bazedoxifene and its preparation method and application. The bazedoxifene derivative is used for gp130 small molecule inhibitor, the compound is a compound shown in formula (I), or a pharmaceutically acceptable salt or ester thereof, and relates to the application of tumor-related activity and the like, in particular the application in preparing drugs for preventing and / or treating diseases related to tumors, especially colorectal cancer.

A drug delivery device may include a housing defining a longitudinal axis and having an opening and a drug storage container including a delivery member having an insertion end configured to extend at least partially through the opening during a delivery state. The device may also include plunger moveable toward the distal end of the drug storage container to expel a drug from the drug storage container through the delivery member, the plunger including a body portion having an inner wall defining an axial chamber and an outer wall cooperating with the inner wall to define a body thickness. The device may further include a plunger biasing member disposed at least partially within the axial chamber, the plunger biasing member configured to urge the plunger toward the distal end of the drug storage container.

This application relates to a drug dosage monitoring device and a drug delivery system. The drug monitoring device includes: a drug reservoir with a drug storage chamber; a piston located within the drug storage chamber; a fixed electrode located outside the second end of the drug reservoir; multiple electrode plates located between the fixed electrode and the second end of the drug reservoir, with the multiple electrode plates and the fixed electrode arranged at intervals; a wire clamping device located on the side of the piston away from the first end of the drug reservoir; and a wire in contact with both the fixed electrode and the wire clamping device. The wire contacts at least one of the multiple electrode plates when the piston moves to different positions within the drug reservoir. The drug dosage monitoring device of this application can determine the position of the piston by detecting the continuity between the fixed electrode and each electrode plate. Based on the position of the piston, the amount of drug output from the drug reservoir in one piston movement and the remaining amount of drug in the drug reservoir can be determined.

Disclosed are methods and apparatus for delivering an active pharmaceutical ingredient (API) to a substrate, such as an edible. In particular, an API-containing liquid is dosed from a dosing head in small increments. Because the volume of API-containing liquid dosed in each increment is known, and the concentration of API in the API-containing liquid is known, the amount of API incrementally driven out of the dosing head in the API-containing liquid is known. Among the API driven out of the dosing head, a majority can be delivered to the substrate, for instance as individual successive droplets or as a stream. A minority can remain adhered to the dosing head as a residual API. A wash fluid can be applied to the dosing head to remove the residual API and deliver the residual API to the substrate.

A pharmaceutical product for administration of an anti HER2 antibody-drug conjugate in combination with an ATR inhibitor is provided. The anti-HER2 antibody-drug conjugate is an antibody-drug conjugate in which a drug linker represented by the following formula (wherein A represents the connecting position to an antibody) is conjugated to an anti-HER2 antibody via a thioether bond. Also provided is a therapeutic use and method wherein the antibody-drug conjugate and the ATR inhibitor are administered in combination to a subject: Formula (I):

The present disclosure relates to an apparatus that automates the transfer of liquid medicine between containers using a syringe, and is characterized by including a housing, a syringe automation unit, a liquid medicine container transfer automation unit, and a control unit.

The application belongs to the technical field of antitumor drugs, and particularly relates to an AuNRs@L / D-Ag2S QDs complex, a preparation method and application thereof. Sodium polystyrene sulfonate is electrostatically adsorbed on AuNRs to obtain 1-PSS-AuNRs; polyallylamine hydrochloride is electrostatically adsorbed on 1-PSS-AuNRs to obtain 2-PAH-AuNRs; polyallylamine hydrochloride is electrostatically adsorbed on 2-PAH-AuNRs to obtain a non-chiral nanomaterial; and the non-chiral nanomaterial is covalently crosslinked with L / D-Ag2S QDs to obtain the AuNRs@L / D-Ag2S QDs complex. The application combines the efficient photo-thermal conversion characteristics of AuNRs with the chiral-dependent targeting and potential fluorescence imaging ability of chiral Ag2S quantum dots by constructing a complex structure, so that a novel nanodiagnostic and therapeutic agent with efficient photo-thermal performance and chiral selectivity is obtained.